Diabetes Antibody Standardization Program: Evaluation of Assays for Autoantibodies to Glutamic Acid Decarboxylase and Islet Antigen-2

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2008 Apr 1

PMID 18373080

Citations 116

Authors

C Torn

P W Mueller

M Schlosser

E Bonifacio

P J Bingley

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Islet autoantibodies are important in diabetes classification and risk assessment, and as endpoints in observational studies. The Diabetes Autoantibody Standardization Program (DASP) aims to improve and standardise measurement of autoantibodies associated with type 1 diabetes. We report results for glutamic acid decarboxylase autoantibodies (GADA) and islet antigen-2 autoantibodies (IA-2A) from three DASP workshops (2002--2005).

Methods: Up to 60 laboratories in 18 countries participated in each workshop. Participants received coded serum aliquots from 50 patients with newly diagnosed type 1 diabetes (median age 18 years, range 9-35 years) and 100 blood donor controls. Results were analysed using receiver operator characteristic (ROC) curves with sensitivity adjusted to 95% specificity in workshop controls.

Results: GADA assays performed well in all three workshops (median area under the ROC curve [AUC] 0.94; interquartile range 0.91-0.95) and performance was similar to DASP 2000. Performance of IA-2A assays improved over the workshop programme. Median AUC was 0.81 (interquartile range 0.79-0.83) in DASP 2002, 0.82 (interquartile range 0.78-0.84) in 2003, and 0.85 (interquartile range 0.82-0.87) in 2005 (p < 0.0001). Performance of GADA ELISA improved between 2002 and 2005, and, in DASP 2005, achieved higher median AUC and adjusted sensitivity than RIA. IA-2A ELISA improved and, in DASP 2005, achieved AUCs equivalent to in-house RIA. Assays using IA-2ic or full length IA-2 clones were more sensitive than those using IA-2bdc, with higher AUC (p = 0.004).

Conclusions/interpretation: GADA and IA-2A assays perform well in discriminating health and disease. The workshop format highlights systematic differences related to assay method and allows full evaluation of novel methods. The programme of autoantibody workshops in type 1 diabetes provides a model for other autoimmune diseases.

Citing Articles

Islet autoantibodies in Thai individuals diagnosed with type 1 diabetes before 30 years of age: a large multicentre nationwide study.

Plengvidhya N, Suthon S, Nakdontri T, Teerawattanapong N, Ingnang S, Tangjittipokin W Diabetologia. 2025; .

PMID: 39971754 DOI: 10.1007/s00125-025-06373-y.

Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA.

Aleman-Contreras R, Gomez-Diaz R, Noyola-Garcia M, Mondragon-Gonzalez R, Wacher N, Ferreira-Hermosillo A Life (Basel). 2024; 14(5).

PMID: 38792571 PMC: 11122504. DOI: 10.3390/life14050550.

Multi-omics Investigations in Endocrine Systems and Their Clinical Implications.

Peliciari-Garcia R, de Barros C, Secio-Silva A, de Barros Peruchetti D, Romano R, Bargi-Souza P Adv Exp Med Biol. 2024; 1443:187-209.

PMID: 38409422 DOI: 10.1007/978-3-031-50624-6_10.

Prevalence of Positivity for Diabetes-Associated Autoantibodies in Individuals with Type 2 Diabetes and Their Further Characterisation: Cross-sectional Study from Slovakia.

Roncakova M, Davani A, Mikusova V, Sagova I, Novodvorsky P, Martinka E Diabetes Ther. 2023; 14(9):1537-1548.

PMID: 37421585 PMC: 10363090. DOI: 10.1007/s13300-023-01440-2.

Improving diagnostic accuracy of 3 Screen ICA ELISA kit in the identification of Japanese type 1 diabetes.

Kawasaki E, Jinnouchi H, Maeda Y, Okada A, Ito Y, Kawai K J Diabetes Investig. 2023; 14(9):1081-1091.

PMID: 37293690 PMC: 10445208. DOI: 10.1111/jdi.14038.

References

Gale E, Bingley P, Emmett C, Collier T . European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004; 363(9413):925-31. DOI: 10.1016/S0140-6736(04)15786-3. View

. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20(7):1183-97. DOI: 10.2337/diacare.20.7.1183. View

Chan E, Fritzler M, Wiik A, Andrade L, Reeves W, Tincani A . AutoAbSC.Org -- Autoantibody Standardization Committee in 2006. Autoimmun Rev. 2007; 6(8):577-80. DOI: 10.1016/j.autrev.2007.05.001. View

Dittler J, Seidel D, Schenker M, Ziegler A . GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives. Diabetes. 1998; 47(4):592-7. DOI: 10.2337/diabetes.47.4.592. View

Mire-Sluis A, Das R, Lernmark A . The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia. 2000; 43(10):1282-92. DOI: 10.1007/s001250051524. View

Greenbaum C, Palmer J, Kuglin B, Kolb H . Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of.... J Clin Endocrinol Metab. 1992; 74(5):1040-4. DOI: 10.1210/jcem.74.5.1569152. View

Bingley P, Bonifacio E, Mueller P . Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes. 2003; 52(5):1128-36. DOI: 10.2337/diabetes.52.5.1128. View

Hagopian W, Lernmark A, Rewers M, Simell O, She J, Ziegler A . TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann N Y Acad Sci. 2006; 1079:320-6. DOI: 10.1196/annals.1375.049. View

Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley P . Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia. 1995; 38(7):816-22. DOI: 10.1007/s001250050358. View

10.

Stern M . Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization. J Pediatr Gastroenterol Nutr. 2001; 31(5):513-9. DOI: 10.1097/00005176-200011000-00012. View

11.

Seissler J, Morgenthaler N, Achenbach P, Lampeter E, Glawe D, Payton M . Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nikotinamid Interventions-Studie. Diabetologia. 1996; 39(11):1351-6. DOI: 10.1007/s001250050582. View

12.

Achenbach P, Schlosser M, Williams A, Yu L, Mueller P, Bingley P . Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol. 2006; 122(1):85-90. DOI: 10.1016/j.clim.2006.09.004. View

13.

Bonifacio E, Boitard C, Gleichmann H, Shattock M, Molenaar J, Bottazzo G . Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. Diabetologia. 1990; 33(12):731-6. DOI: 10.1007/BF00400345. View

14.

Bonifacio E, Cobain T, Dawkins R, Griffiths M, Kalden J, Peter J . Comparison and standardization of measurement of anti-acetylcholine receptor antibody between laboratories. Autoimmunity. 1988; 1(1):59-66. DOI: 10.3109/08916938808997177. View

15.

Hagen E, Andrassy K, Chernok E, Daha M, Gaskin G, Gross W . The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods. 1993; 159(1-2):1-16. DOI: 10.1016/0022-1759(93)90136-u. View

16.

Verge C, Stenger D, Bonifacio E, Colman P, Pilcher C, Bingley P . Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes. 1998; 47(12):1857-66. DOI: 10.2337/diabetes.47.12.1857. View

17.

Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay I . UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997; 350(9087):1288-93. DOI: 10.1016/s0140-6736(97)03062-6. View